NCT05307237Completed
Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)
Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital: Cloud-Based Real-Time Glucose Evaluation and Management System (Cyber GEMS)
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system in the hospital to test a dynamic and digitized, team-based approach to glucose management in an underserved and understudied, yet high-risk population. A digital dashboard will facilitate real-time, remote monitoring of a large volume of patients simultaneously; automatically identify and prioritize patients for intervention; and will detect any and all potentially dangerous hypoglycemic episodes in a hospital environment. The study will focus on clinical metrics of glucose control and infection that are in-line with patient priorities and US hospital quality initiatives.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 518 (actual)
- First submitted
- 11 Nov 2021
- Start date
- 19 Apr 2022
- Primary completion date
- 17 Dec 2025
- Lead sponsor
- Scripps Whittier Diabetes Institute
- Diseases
- Type 2 diabetes
- NCT number
- NCT05307237
What you commit to
- Study type: Interventional
- Participants enrolled: 518
- From 19 Apr 2022 to the primary completion date, 17 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current participation in any medication or device research study;
Other illness
- Known allergy to adhesives;
- Any other condition that Multiple Principal Investigator (MPI) Philis-Tsimikas or the attending physician deems contraindicated
Other
- Anticipated length of stay \< 24 hours;
- Current or anticipated ICU placement;
- Does not speak English or Spanish;
- Pregnant;
Who the study is looking for
- Documented previous or current Type 2 Diabetes (T2D) diagnosis as defined by either diagnosis in the chart or an HbA1c \> or = to 6.5% in the last 90 days
- Either on subcutaneous (SQ) insulin orders, or greater than two serum or Point of Care (POC) glucose \> or = 200 mg/dL in most recent 24 hours of admission
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Scripps Mercy Hospital Coordinator of this site? Confirm its status | Chula Vista | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.